{
    "nctId": "NCT00898573",
    "briefTitle": "Lapatinib Resistance in Patients With Breast Cancer",
    "officialTitle": "Study of Resistance Mechanisms Against Lapatinib in Patients With ErbB-2-Positive Breast Cancers",
    "overallStatus": "WITHDRAWN",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Secondary ErbB2 mutations",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Pathologically confirmed invasive breast cancer\n\n  * ErbB2-positive disease\n* Has received or is currently receiving lapatinib ditosylate\n\n  * Documented clinical benefit while receiving lapatinib ditosylate (e.g., stable disease of \u2265 12 weeks duration OR a radiographic response)\n* Must have tumor tissue samples available for research studies\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* Menopausal status not specified\n* Not pregnant\\*\n* Coagulation profile normal\\*\n* Platelet count \\> 100,000/mm\u00b3\\* NOTE: \\*For patients requiring a post-treatment biopsy\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* Concurrent chemotherapy or trastuzumab (Herceptin\u00ae) allowed\n* No concurrent anticoagulants, including warfarin or low-molecular weight heparin\\*\n* No concurrent antiplatelet therapy, including aspirin, clopidogrel, or other antiplatelet agents\\* NOTE: \\*For patients requiring a post-treatment biopsy",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}